medicine-products/sonosite-micromaxx-16762-1/;msg18067;topicseen
| We're sorry, that page (http://www.bio-medicine.org/medicine-products/sonosite-micromaxx-16762-1/;msg18067;topicseen) was not found. Search medicine products sonosite micromaxx 16762 1 ;msg18067;topicseen at Google Search medicine products sonosite micromaxx 16762 1 ;msg18067;topicseen at Yahoo Search medicine products sonosite micromaxx 16762 1 ;msg18067;topicseen at Msn |
Breaking Biology Technology:Dendreon Appoints Hans Bishop as Chief Operating Officer 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
[0] Dendreon Appoints Hans Bishop as Chief Operating Officer[0] Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years[0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Breaking Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Uroplasty Reports First Fiscal Quarter Results 53547 1Uroplasty Reports First Fiscal Quarter Results 53547 2Uroplasty Reports First Fiscal Quarter Results 53547 3Uroplasty Reports First Fiscal Quarter Results 53547 4Uroplasty Reports First Fiscal Quarter Results 53547 5Uroplasty Reports First Fiscal Quarter Results 53547 6Uroplasty Reports First Fiscal Quarter Results 53547 7Uroplasty Reports First Fiscal Quarter Results 53547 8Uroplasty Reports First Fiscal Quarter Results 53547 9Uroplasty Reports First Fiscal Quarter Results 53547 10Uroplasty Reports First Fiscal Quarter Results 53547 11Uroplasty Reports First Fiscal Quarter Results 53547 12Uroplasty Reports First Fiscal Quarter Results 53547 13Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 1Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 2Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 3Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 4Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 5Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 6Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 7Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 8Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 9Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 10
[0] AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens[0] OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months[0] Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |